The U.S. Food and Drug Administration has approved PTC Therapeutics’ Kebilidi (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.
This article was originally published on MedicalXpress.com